Skip to main content

Table 1 Demographic characteristic for COPD patients with and without GORD

From: Gastro-oesophageal reflux disease increases the risk of intensive care unit admittance and mechanical ventilation use among patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study

Characteristic With GORD ( n = 1,210) Without GORD ( n = 2,420) P value
Male 807 (66.69) 1,621 (66.98) 0.861a
Age 63.4 (±12.16) 63 (±12.38) 0.414a
Age category    
 40 to 50 214 (17.69) 461 (19.05) 0.795a
 51 to 60 267 (22.07) 516 (21.32)  
 61 to 70 309 (25.54) 632 (26.12)  
 71 to 80 324 (26.78) 616 (25.45)  
  ≥ 80 96 (7.93) 195 (8.06)  
CCI category    
 0 22 (1.82) 55 (2.27) 0.757a
 1 to 3 563 (46.53) 1,142 (47.19)  
 4 to 6 415 (34.3) 802 (33.14)  
  ≥ 7 210 (34.3) 421 (17.4)  
Proxy COPD severity 40 (3.31) 79 (3.26) 0.947a
COPD medication    
 SABA 171 (14.13) 396 (16.36) 0.081
 LABA 12 (0.99) 22 (0.91) 0.808
 SAMA 157 (12.98) 344 (14.21) 0.307
 Theophylline 1,071 (88.51) 2,066 (85.37) 0.009
 ICS 42 (3.43) 65 (2.67) 0.187
 LAMA 15 (1.24) 26 (1.07) 0.657
Vaccines    
 Influenza and pneumococcal 454 (37.52) 890 (36.78) 0.662
Residential area    
 Urban 675 (55.79) 1,363 (56.32) 0.888a
 Suburban 418 (34.55) 817 (33.76)  
 Rural 117 (9.67) 240 (9.92)  
Occupation category    
 1 325 (26.86) 714 (29.5) 0.098a
 2 535 (44.21) 1,078 (44.55)  
 3 350 (28.93) 628 (25.95)  
Monthly insurance premium ($NT)b    
 No fee 274 (22.64) 628 (25.95) 0.079a
 1 to 19,199 332 (27.44) 602 (24.88)  
 19,200 to 23,999 400 (33.06) 817 (33.76)  
  ≥ 24,000 204 (16.86) 373 (15.41)  
  1. Data presented as n (%) or mean (± standard deviation). CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; NT, new Taiwan dollar; SABA, short-acting β2-agonists; SAMA, short-acting muscarinic antagonists. aStandard difference. bUS$1 $NT30.